Global In vivo Contract Research Organization Market Size By Type (Rodent Based, Non Rodent Based), By Application (Autoimmune, Pain Management), By Region, And Segment Forecasts, 2023 to 2032

The Global In Vivo Contract Research Organization (CRO) Market was valued at USD 4.6 billion in 2023 and is projected to reach USD 8.3 billion by 2031, growing at a CAGR of 7.5% during the forecast period from 2023 to 2031. The market's expansion is fueled by the increasing outsourcing of preclinical studies by pharmaceutical and biotechnology companies, growing R&D investments, and the demand for cost-effective and time-efficient drug development services. In vivo CROs play a vital role in drug discovery by conducting animal-based testing and providing insights into the pharmacokinetics, safety, and efficacy of therapeutic compounds before human trials.

Drivers:

1. Surge in Drug Discovery and Development: The rise in chronic diseases and complex health conditions has led to increased investments in innovative drug development. In vivo CROs provide essential preclinical services, accelerating time-to-market for new therapies.

2. Outsourcing Trend Among Pharma & Biotech Firms: Cost and time pressures are pushing drug developers to outsource non-core functions such as in vivo testing. This strategic outsourcing helps reduce overhead while accessing specialized expertise and infrastructure.

3. Regulatory Compliance and Expertise: CROs are well-versed in evolving regulatory frameworks (FDA, EMA, etc.), enabling sponsors to navigate complex approval pathways with accurate data collection and documentation.

Restraints:

1. Ethical Concerns and Regulatory Hurdles: Animal testing in drug research faces increasing scrutiny and ethical pushback, leading to stringent regulations that may limit market operations or delay study timelines.

2. High Operational Costs and Infrastructure Needs: Setting up and maintaining high-quality in vivo research facilities demands significant capital and skilled workforce, which may restrain smaller firms or newer entrants.

Opportunity:

1. Emerging Biotech Startups and Personalized Medicine: The growing biotech ecosystem and personalized medicine focus present significant opportunities for CROs to partner in niche research areas requiring customized in vivo models.

2. Technological Integration in Preclinical Studies: Advanced imaging techniques, AI-driven analytics, and telemetry systems in animal models are transforming data accuracy and efficiency, creating scope for differentiation among CROs.

Market by System Type Insights:

By system type, the Rodent-Based Testing segment dominated the market in 2023 due to rodents' genetic similarities with humans, cost-effectiveness, and ease of handling. However, the Non-Rodent Mammals segment is expected to grow steadily, driven by its critical role in toxicology and safety pharmacology for specialized therapies and biologics.

Market by End-Use Insights:

Based on end use, Pharmaceutical & Biotechnology Companies were the largest revenue contributors in 2023, accounting for more than 60% of the market share. These companies rely heavily on in vivo CROs to meet aggressive development timelines and regulatory compliance standards. Meanwhile, Academic & Research Institutes are anticipated to gain traction due to increasing grant funding and collaborative public-private research initiatives.

Market by Regional Insights:

North America led the global in vivo CRO market in 2023, driven by the strong presence of leading CROs, robust drug pipeline, and regulatory support. The Asia-Pacific region is projected to witness the highest CAGR during the forecast period, attributed to the region's cost advantages, improving regulatory landscape, and increasing R&D expenditure in countries such as China and India.

Competitive Scenario:

Key players in the global in vivo CRO market include Charles River Laboratories, Envigo, Labcorp Drug Development, The Jackson Laboratory, PRA Health Sciences, Syneos Health, Taconic Biosciences, and WuXi AppTec. These firms are focused on expanding service portfolios, forming strategic alliances, and investing in innovative preclinical platforms. For example:

In 2023, Charles River expanded its discovery services with a new facility in the U.S. to support growing demand from small and mid-sized biotechs.

In 2022, WuXi AppTec enhanced its toxicology services by integrating advanced AI for real-time monitoring and data analysis in animal testing.

Labcorp acquired a niche CRO in 2024 to bolster its oncology-focused preclinical service offering.

Scope of Work – Global In Vivo Contract Research Organization Market

Report Metric Details

Market Size (2023) USD 4.6 billion

Projected Market Size (2031) USD 8.3 billion

CAGR (2023–2031) 7.5%

Market Segments By System Type (Rodent-Based, Non-Rodent), By End-use (Pharma, Academic), By Region

Growth Drivers Rising drug development, outsourcing trend, regulatory expertise

Opportunities Technological integration, biotech innovation, Asia-Pacific expansion

Key Market Developments:

May 2023: Charles River announced the launch of a cloud-based preclinical data platform enhancing collaboration between sponsors and CRO scientists.

August 2024: Taconic Biosciences expanded its humanized mouse model portfolio to support immuno-oncology drug research.

February 2025: Syneos Health entered a multi-year agreement with a biotech firm for full-service preclinical development across multiple therapeutic areas.

FAQs:

1) What is the current market size of the Global In Vivo Contract Research Organization Market?

The market was valued at USD 4.6 billion in 2023.

2) What is the major growth driver of the Global In Vivo Contract Research Organization Market?

The major driver is the rising demand for outsourced preclinical research services to reduce drug development time and cost.

3) Which is the largest region during the forecast period in the Global In Vivo Contract Research Organization Market?

North America remains the largest region due to its established CRO infrastructure and strong R&D activity.

4) Which segment accounted for the largest market share in Global In Vivo Contract Research Organization Market?

The Pharmaceutical & Biotechnology Companies segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global In Vivo Contract Research Organization Market?

Key players include Charles River Laboratories, Labcorp Drug Development, WuXi AppTec, Taconic Biosciences, and Syneos Health.